Propanc Biopharma, Inc., formerly Propanc Health Group Corporation, is an early-stage healthcare company that is focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. The Company has developed a composite formulation of anti-cancer compounds, which together exert a range of effects designed to control or prevent tumors from recurring and spreading through the body. The Company's solution is to develop and commercialize a long-term therapy to prevent tumor recurrence and metastases. It is developing pro-enzyme therapy for the treatment and prevention of the development of carcinomas from solid tumors. The Company's products include PRP and PRP-DCM. The Company's PRP is a formulation consisting of two pro-enzymes: trypsinogen and chymotrypsinogen, plus the enzyme amylase (1, 4-alpha-D-glucan glucanohydrolase). The pro-enzymes in PRP, typsinogen and chymotrypsinogen, exhibit specificity for tumor cells and not normal cells.